You have 9 free searches left this month | for more free features.

City

Beverly Hills (1)

Charlotte (1)

Clearwater (1)

Dallas (1)

Indianapolis (1)

Condition

Cutaneous Lupus Erythematosus (1)

Cutaneous Lupus Erythematosus (CLE) (1)

Rheumatoid Arthritis (1)

Overall Status

Not yet recruiting (1)

Terminated (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Gilead Sciences (3)

Collaborator

Intervention

gs-5718 (3)

gs-5718 placebo (1)

placebo (1)

placebo to match gs-5718 (1)

placebo to match tofacitinib (1)

tofacitinib 5 mg (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

gs-5718

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Cutaneous Lupus Erythematosus (CLE) Trial (GS-5718, GS-5718 Placebo)

Not yet recruiting

Cutaneous Lupus Erythematosus (CLE)

GS-5718
GS-5718 Placebo

(no location specified)

Dec 6, 2022

Cutaneous Lupus Erythematosus Trial in United States (GS-5718, Placebo)

Terminated

Cutaneous Lupus Erythematosus

GS-5718
Placebo

Beverly Hills, California
+4 more

Nov 17, 2022

Rheumatoid Arthritis Trial (GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg)

Withdrawn

Rheumatoid Arthritis

GS-5718
+3 more

(no location specified)

May 11, 2022